Izvorni znanstveni članak
https://doi.org/10.3325/cmj.2016.57.239
Glycoprotein YKL-40: a novel biomarker of chronic graftvs- host disease activity and severity?
Nadira Duraković
orcid.org/0000-0001-5842-0911
; University of Zagreb, School of Medicine, Zagreb, Croatia
Ivan Krečak
; General Hospital Šibenik, Šibenik, Croatia
Zinaida Perić
; University of Zagreb, School of Medicine, Zagreb, Croatia
Milan Milošević
; University of Zagreb, School of Medicine, Zagreb, Croatia
Lana Desnica
; Department of Internal Medicine, Division of Hematology, University Hospital Center, Zagreb, Croatia
Dražen Pulanić
; Department of Internal Medicine, Division of Hematology, University Hospital Center, Zagreb, Croatia
Iskra Pusic
; Division of Oncology, Section of Bone Marrow Transplant and Leukemia, Department of Medicine, Washington UniversitySchool of Medicine, St Louis, MO,USA
Vesna Kušec
; Clinical Department of Laboratory Diagnosis, University Hospital Center Zagreb, Zagreb, Croatia
Radovan Vrhovac
; University of Zagreb, School of Medicine, Zagreb, Croatia
Steven Z. Pavletic
; Experimental Transplantation and Immunology Branch, Center for Cancer Research, National CancerInstitute, National Institutes ofHealth, Bethesda, MD, USA
Damir Nemet
; University of Zagreb, School of Medicine, Zagreb, Croatia
Sažetak
Aim To investigate whether increased YKL-40 levels positively
correlate with graft-vs-host disease (cGVHD) activity
and severity and if YKL-40 could serve as a disease biomarker.
Methods This case-control study was conducted at the
University Hospital Centre Zagreb from July 2013 to October
2015. 56 patients treated with hematopoietic stem
cell transplantation (HSCT) were included: 35 patients with
cGVHD and 21 without cGVHD. There was no difference
between groups in age, sex, median time from transplant
to study enrollment, intensity of conditioning, type of donor,
or source of stem cells. Blood samples were collected
at study enrollment and YKL-40 levels were measured with
ELISA. Disease activity was estimated using Clinician’s Impression
of Activity and Intensity of Immunosuppression
scales and disease severity using Global National Institutes
of Health (NIH) score.
Results YKL-40 levels were significantly higher in cGVHD
patients than in controls (P = 0.003). The difference remained
significant when patients with myelofibrosis were
excluded from the analysis (P = 0.017). YKL-40 level significantly
positively correlated with disease severity (P < 0.001;
correlation coefficient 0.455), and activity estimated using
Clinician’s Impression of Activity (P = 0.016; correlation coefficient
0.412) but not using Intensity of Immunosuppression
(P = 0.085; correlation coefficient 0.296).
Conclusion YKL-40 could be considered a biomarker of
cGVHD severity and activity. However, validation in a larger
group of patients is warranted, as well as longitudinal
testing of YKL-40 levels in patients at risk of developing
cGVHD.
Ključne riječi
Hrčak ID:
169607
URI
Datum izdavanja:
15.6.2016.
Posjeta: 914 *